The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Updated results for the advanced esophageal carcinoma cohort of the phase 1b KEYNOTE-028 study of pembrolizumab.
 
Toshihiko Doi
Consulting or Advisory Role - AstraZeneca; Bayer Yakuhin; Chugai Pharma; Kyowa Hakko Kirin; Lilly Japan; Merck Serono; MSD; Nippon Boehringer Ingelheim; Novartis; Otsuka
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Eisai (Inst); Janssen (Inst); Lilly Japan (Inst); Merck Serono (Inst); MSD (Inst); NanoCarrier (Inst); Novartis (Inst); Pfizer (Inst); Quintiles (Inst); Sanofi (Inst); Sumitomo Group (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Sarina Anne Piha-Paul
Research Funding - Abbvie; Bayer; Biomarin; Cerulean Pharma; Curis; Five Prime Therapeutics; GlaxoSmithKline; Helix BioPharma; Incyte; Merck; Novartis; Puma Biotechnology; Samumed; XuanZhu
 
Shadia Ibrahim Jalal
No Relationships to Disclose
 
Hieu Mai-Dang
Employment - Merck
Stock and Other Ownership Interests - Johnson & Johnson (I)
 
Sanatan Saraf
Employment - Merck
 
Minori Koshiji
Employment - Merck
 
Ildiko Csiki
Employment - Merck
 
Jaafar Bennouna
Honoraria - Boehringer Ingelheim; Novartis; Pierre Fabre; roche
Consulting or Advisory Role - Boehringer Ingelheim; Novartis; Pierre Fabre; Roche